Raymond Quigley, MD
Pediatric Nephrology · Dallas, TXNPI 1689635690
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,628 of the $6,920 with a category attached, or 95.8%. Akebia Therapeutics Inc accounts for 77.8% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2020 at $5,383 and has fallen 99.7% since, to $15 in 2025.
Across 7 payments — averaging $988.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Akebia Therapeutics Inc$5K
- Alnylam Pharmaceuticals Inc.$1K
- AstraZeneca$215
- Novo Nordisk$25
- Medtronic$23
Across 22 payments — averaging $4274.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$47K
- Genentech, Inc.$46K
- Medtronic$1K
What the payments were for
- Consulting fees$6,62896%
- Speaking & faculty fees$2003%
- Food & beverage$921%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Akebia Therapeutics Inc | 1 | $5,383 |
| Alnylam Pharmaceuticals Inc. | 2 | $1,274 |
| AstraZeneca | 2 | $215 |
| Novo Nordisk | 1 | $25 |
| Medtronic | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AURYXIA$5,383
How this compares
$6,920 in reported general payments places this provider in the 85th percentile of 61 pediatric nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Esomeprazole Magnesium | 17 | $863 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 14 | $86 |
Paid to pharmacies, not to this prescriber.
Other pediatric nephrology in Dallas
- Albert QuanDallas$6K
- Mouin SeikalyDallas$4K
- Elizabeth BrownDallas$390
- Smitha VidiDallas$53
- Amanda ClarkDallas$29
- Amy BeckerCorpus Christi$77K
- Mini MichaelHouston$25K
- Rita SwinfordHouston$25K
- Ewa ElenbergHouston$16K
- Robert GillespieFort Worth$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.